Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201

By Chris Wack

Creative Medical Technology Holdings shares were up 37% at $6.50 after the company said it received Food and Drug Administration authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing Type 1 Diabetes Mellitus in high-risk individuals.

The stock hit its 52-week low of $3.93 on Feb. 24, and is up 8% in the past 12 months.

This therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.

Creative Medical said its CELZ-201 has a multi-target mechanism to address abnormal glucose tolerance, a T1D precursor, at the cellular level.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

03-07-24 1029ET